Nasus Pharma Ltd. · AMEX:NSRX
Nasus Pharma — Investor Presentation (December 2025)
31 slides from Nasus Pharma's investor presentation, December 2025
Slide 1: A New Frontier in Intranasal Drug Delivery
Please migrate color palette to match website A NEW FRONTIER IN INTRANASAL DRUG DELIVERY A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exchange NYSE Ame
Slide 2: Forward Looking Statements; Disclaimer
Forward Looking Statements; Disclaimer This presentation of Nasus Pharma Ltd. (the “Company”, “Nasus” or “Nasus Pharma”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities law. Words such as “expects,” “intends,” “pla
Slide 3: Company Highlights
Company Highlights Nasus is Uniquely Positioned to Address Medical Emergencies via Intranasal Drug Delivery NS002 was designed to address Proprietary Nasax powder Use of well-known active limitations of injectable technology aims to enhance pharmaceutical ingredients Epinephrine, with a needle-free,
Slide 4: Robust Asset Pipeline Setting Up Potential for Long Term Growth
Robust Asset Pipeline Setting Up Potential for Long Term Growth Addressing Significant Medical Emergencies Drug Candidate Molecule Indication Preclinical Phase 1 Phase 2 Pivotal Trial Next Milestone Results from Phase Phase 2 single dose PK study completed in March 2023 2 repeated dose NS002 Epineph
Slide 5: Proprietary Nasax Platform Enables Superior Drug Absorption
Proprietary Nasax Platform Enables Superior Drug Absorption Powder formulation can reach all parts of nasal cavity; The greater intranasal absorption area enables faster delivery and higher maximal drug concentration compared to liquid formulations Liquid formulation Powder formulation Liquid Spray
Slide 6: NS002: Intranasal Epinephrine
NS002: INTRANASAL EPINEPHRINE
Slide 7: Anaphylaxis: A Time-Critical Medical Emergency
Anaphylaxis: A Time-Critical Medical Emergency Anaphylaxis is a severe allergic reaction; fatal in ~1% of cases1 The standard of care for anaphylaxis is Epinephrine – this is typically self-administered via an Epinephrine auto-injector (EAI) or given via intramuscular (IM) injection by a healthcare
Slide 8: Anaphylaxis: A Growing Opportunity in a Large Market
Anaphylaxis: A Growing Opportunity in a Large Market Estimated prevalence of anaphylaxis ~1-3% among the global population1 ~$2.3B Global Epinephrine market in 20242 ~40M Patients with type 1 allergies in the U.S.3 +6.5% From 2010 to 20233 CAGR Patients experience severe type I ~20 M allergic reacti
Slide 9: NS002 Designed to Address the Limitations of Intramuscular Epinephrine
NS002 Designed to Address the Limitations of Intramuscular Epinephrine The proposed solution: NS002 Autoinjectors1 with a 12-18 month Product candidate aims to offer shelf-life a needle-free solution, longer shelf-life, easily administered Large and bulky to carry2 15cm by trained professionals and
Slide 10: NS002: Completed Milestones
NS002: Completed Milestones Completed Completed NS002 NS002/EpiPen® single pilot study dose PK Phase 2 study Q3 2021 Q2 2022 Q1 2023 Pre-IND meeting w/ FDA 10
Slide 11: NS002: Pilot Study Overview
NS002: Pilot Study Overview Study goal: Test NS002’s Epinephrine bioavailability following allergenic challenge PK/PD measurements: plasma Epinepherine, Tmax, T100, AUC, SBP, HR 12 healthy adults with allergic rhinitis (9 male, 3 female) Screening: positive to skin allergen test Period 1 Period 2 2-
Slide 12: Pilot Study Results Show NS002 Epinephrine Absorbed Faster than EpiPen
Pilot Study Results Show NS002 Epinephrine Absorbed into Bloodstream Faster than EpiPen® Pilot Study Pharmacokinetics (PK) Plasma epinephrine – geometric mean – 60 min. n=12 12
Slide 13: NS002 Pilot Study Demonstrated Faster and Higher Maximal Epinephrine Absorption
NS002 Pilot Study Demonstrated Faster and Higher Maximal Epinephrine Absorption Compared to EpiPen® Pilot study PK – baseline corrected time medians Area Under Curve Tmax median (min.) n=12 n=12 20.00 16.50 15.00 Tmax (min.) 9.00 8.98 10.00 5.99 5.00 2.50 0.00 EpiPen Nasus 1.6mg Nasus Nasus 3.2mg Na
Slide 14: NS002 PD Results Demonstrated Comparable Epinephrine Activity to EpiPen
NS002 PD Results Demonstrated Comparable Epinephrine Activity to EpiPen® Pilot study pharmacodynamics (PD) Systolic Blood Pressure n=12 125 120 SBP (mm Hg) EpiPen 115 Nasus 1.6mg normal condition 110 Nasus 1.6mg allergenic challenge 105 Nasus 3.2mg normal condition Nasus 3.2mg allergenic challenge 1
Slide 15: NS002: Phase 2 Study Design
NS002: Phase 2 Study Designed to Assess Safety and Tolerability, Test Bioavailability, and Optimize Dose for Phase 3 1 week 1 week Arm 1: N=6 B C A Nasus spray 3.6mg Nasus spray 4.0mg On each dosing day: EpiPen® in one nostril in one nostril Screening PK sampling: 12 healthy -1 to 2hr. (13 samples)
Slide 16: Phase 2 Study: More Patients Achieved Therapeutic Threshold at 6 Minutes
Phase 2 Study: More Patients Achieved Hemodynamic Therapeutic Threshold of Epinephrine by NS002 Compared to EpiPen® at 6 Minutes Phase 2 PK results Plasma Epinephrine Results 12 healthy subjects 6min EpiPen® 55 % Nasus 3.6mg 72 % Nasus 4.0mg 91% Proportion of subjects achieving clinical threshold of
Slide 17: Phase 2 Study: NS002 Achieves Faster Epinephrine Plasma Concentration
Phase 2 Study: NS002 Achieves Faster Epinephrine Plasma Concentration than EpiPen® Mean AUC0-4min +SD n=12 Mean AUC0-10min +SD n=12 70 140 60 120 Mean AUC h*pg/mL 50 Mean AUC h*pg/mL 100 40 80 27.44 63.96 30 50.99 60 20 14.17 40 27.38 10 5.85 20 0 Phase 2 EpiPen Nasus 3.6mg Nasus 4.0mg 0 EpiPen Nasu
Slide 18: Phase 2 Study: Faster Absorption and Greater Concentration vs EpiPen
Phase 2 Study: NS002 Achieves Faster Absorption and Greater Concentration of Epinephrine Compared to EpiPen® – Including Time to Hemodynamic Therapeutic Threshold 100pg/ml Phase 2 Results - Cmax, Tmax and T100pg/mL Tmax (median, minutes) n=12 T100pg/mL (median, minutes) n=12 Cmax (Geometric mean + S
Slide 19: Phase 2 Study: Comparable Epinephrine Activity to EpiPen
Phase 2 Study: NS002 Demonstrated Comparable Epinephrine Activity to EpiPen® Heart Rate n=12 Systolic Blood Pressure n=12 140 90 130 85 Systolic BP (mean) Phase 2: 80 HR (mean) 120 PD results 110 75 70 100 65 90 0 20 40 60 80 100 120 0 20 40 60 80 100 120 Time (min.) Time (min.) Respiration Rate n=1
Slide 20: NS002: Phase 2 Results Summary
NS002: Phase 2 Results Summary NS002 Could Be a Compelling Alternative to Epinephrine Autoinjectors 01 NS002 reached the hemodynamic therapeutic plasma threshold faster than EpiPen® 02 Maximum epinephrine absorption (Tmax) achieved significantly faster compared to EpiPen® 03 Nasax powder was well to
Slide 21: Competitive Landscape Indicates Large Opportunity for Needle-Free Epinephrine
The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine ARS Pharma1 Orexo3 Aquestive4 Nasus Pharma5 (Market Cap $885M) (Market Cap SEK1.3B) (Market Cap $825M) (Market Cap $70M*) PK Parameters EpiPen®5 Neffy (nasal spray) OX640 (nasal powder) ANAPHYLM (sublin
Slide 22: Progression of Anaphylaxis + Epinephrine Onset of Action
Progression of Anaphylaxis + Epinephrine Onset of Action A Medical Emergency Where Every Second Counts and Speed Matters Nasus FMX1002 ARS-1 Neffy Tmax = 10 min1 Tmax = 30 min2 0 5min 10min 15min 20min 25min 30min Time of Drug Administration Serious patient discomfort increases the risk of hospitali
Slide 23: NS002: Clear Roadmap to NDA
NS002: Clear Roadmap to NDA • Following FDA guidance based on the 505b2 regulatory pathway • Demonstration of comparable PK/PD to EpiPen® only requirement for regulatory approval • Repeated dose Ph2 study initiated Q4 2025; interim readout Q1 2026 • Pivotal trial expected to initiate Q3 2026 • Short
Slide 24: NS002: Phase 2 Study Designed to Compare Repeat Dosing
NS002: Phase 2 Study Designed to Compare Bioavailability and PK of Repeat Dosing Results of the first pre-planned interim analysis expected in Q1 2026 Week 7: Week 5: Nasal allergic 2xNS002 4mg challenge L+L nostril 2xNS002 4mg Week 1: L+L nostril Group 1 Nasal allergic Week 2: Week 3: Week 4: 2xEpi
Slide 25: NS001: Intranasal Naloxone
NS001: INTRANASAL NALOXONE 25
Slide 26: Pivotal Study Validated Superiority of Powder over Liquid
Pivotal Study Validated the Superiority of Powder over Liquid, Demonstrating Nasax Platform Delivers Naloxone Faster Compared to Narcan® In our phase 3 (n=42) intranasal naloxone study (NS-001), our formulation provided faster delivery and higher mean absorption of naloxone compared to Narcan® The r
Slide 27: Robust Patent Portfolio
Robust Patent Portfolio Country Filed Patent No./ Publication No. Grant Date/ Pub. Date Status Expiration Date(2) USA 8/20/2017 Term Ended PCT(1) 8/19/2018 WO 2019/038756 A1 National Phase entered 8/19/2038 Australia 8/19/2018 Grant Fee Paid 8/19/2038 Canada 8/19/2018 Office Action due: 10/22/2024 8
Slide 28: Nasus is Uniquely Positioned to Address Medical Emergencies
Proprietary Nasax powder technology designed to enhance intranasal drug absorption Lead product candidate NS002 is needle-free, convenient, and easily administered; aiming to offer an alternative to Epinephrine autoinjectors and directly addressing the currently unmet need Nasus is Uniquely Positive
Slide 29: Leadership Team
Leadership Team Udi Gilboa, Co-Founder & Executive Chairman Mr. Gilboa is a prominent serial life sciences entrepreneur and the co-founder of multiple medical device and pharmaceutical companies. He co-founded and served as director and CFO of BioBlast Ltd (NASDAQ: ORPN), Alcobra Ltd (NASDAQ: ADHD),
Slide 30: A New Frontier in Intranasal Drug Delivery
Please migrate color palette to match website A NEW FRONTIER IN INTRANASAL DRUG DELIVERY A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exchange NYSE Ame
Slide 31: Simplified Supply Chain
Simplified Supply Chain Unidose (UDS) Powder Nasal Spray System (Aptar) Fill, finish, package API Nasal powder (NS002 – epinepherine) manufacture (NS001 – naloxone) 31